雷普里根 RGEN 深 沪
等待开盘 06-24 09:30:00 美东时间
126.37
-0.200
-0.16%
华盛通- 最 高130.73
- 今 开128.16
- 成交量 85.65万股
- 最 低 124.85
- 昨 收 126.57
- 总市值 712.82万
- 52周最高 175.77
- 市盈率 静 146.19
- 换手率 1518.41%
- 52周最低 100.99
- 委 比 52.83%
- 总股本 5.64万
- 历史最高 327.32
- 量 比 0.91
- 振 幅 4.65%
- 历史最低 2.90
- 每 手 1
- 风险率 18.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Citrini看多美股医疗板块新行情，更新“卖铲人”篮子：AI利好叠加周期性改善，复苏信号更明确
曾凭借《2028年全球智能危机》这一“思想实验”报告迅速出圈的独立研究机构的Citrini Research近日对其医疗保健投资组合进行了更新，原因是该公司...
06-10 09:49
Citrini sees new upside in healthcare stocks, updates basket
Citrini Research has updated its healthcare basket as the firm grows increasingly bullish on a recovery in life sciences, bioprocessing, and healthcare infrastructure stocks driven by both cyclical im...
06-09 23:41
美股大行评级 | 火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元
火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元；犹他美容(ULTA)惨遭12家大行下调目标价>>
06-04 11:36
美股大行评级 | 潜在涨幅43%，慧与获11家大行集体上调目标价；最高300美元，Credo获9家大行集体上调目标价
今日重点评级关注：Ascendiant Capital：维持Genasys"买入"评级，目标价从5.5美元升至6美元；Citizens：维持Abivax"跑赢大市"评级，目标价从131美元升至187美元
06-03 11:17
Wolfe Research Assumes Repligen at Outperform, Announces Price Target of $145
Wolfe Research analyst Mike Polark assumes Repligen (NASDAQ:RGEN) with a Outperform rating and announces Price Target of $145.
06-02 19:35
William Blair updates its Conviction List
William Blair has updated its Conviction List of stock picks for June. Analysts added Cloudflare (NET), Fastenal (FAST) and Ethos Technologies (LIFE), while removing Guardant Health (GH), AAON (AAON) ...
06-02 17:19
Repligen CEO Loeillot presents at William Blair Growth Stock Conference
Repligen CEO Loeillot presents at William Blair Growth Stock Conference Repligen to present a company overview at the William Blair 46th Annual Growth Stock Conference in Chicago on June 3 at 10:40 a.m. CT. CEO Olivier Loeillot is scheduled to deliver the presentation. Disclaimer: This news brief wa
05-22 19:30
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
Repligen Corporation will participate in the William Blair 46th Annual Growth Stock Conference in Chicago, IL. CEO Olivier Loeillot will present on June 3rd at 10:40 a.m. CT. A live webcast and replay will be available on Repligen’s Investor Relations website. Repligen develops bioprocessing technologies for biological drug manufacturing, focusing on Filtration, Chromatography, and Process Analytics. The company operates globally with headquarter...
05-22 11:30
Repligen publishes 2025 sustainability report
Repligen publishes 2025 sustainability report Repligen issued its 2025 sustainability report, highlighting 100% renewable electricity across U.S. and European manufacturing operations, covering 96% of global electricity use. Total greenhouse gas emissions were 26,134 tons CO2e, including Scope 3 emi
05-20 19:55
Repligen publishes 2025 corporate sustainability report with ESG disclosures
Repligen publishes 2025 corporate sustainability report with ESG disclosures Repligen published its 2025 corporate sustainability report, outlining progress across products and packaging, operations, talent, supply chain, communities, and pathways to success. The report said U.S. and European manufa
05-20 19:54
